KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial.

Rajesh Pahwa, Elena Moro, Alberto J Espay, Andrew Evans, Marie Saint-Hilaire, Diego Torres-Russotto, Raymond Sanchez, Matthew Leoni, Sridhar Duvvuri, Cari Combs, Ih Chang, Stacey Tringali, Joey Boiser, Cindy Zadikoff, Angelo Antonini

JAMA Neurol 83(5) 452-460

PMID41860533
PMCIDPMC13005179
DOI10.1001/jamaneurol.2026.0590
发表日期2026-03-20
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1.:图注未提示 KM 曲线;Figure 2.:图注未提示 KM 曲线。
摘要

摘要

IMPORTANCE: Tavapadon is an oral, once-daily, selective D1/D5 agonist that may improve Parkinson disease (PD) motor symptoms while minimizing adverse events (AEs) associated with D2/D3 receptor activation. OBJECTIVE: To evaluate the efficacy, safety, and tolerability of tavapadon in adults with early PD. DESIGN, SETTING, AND PARTICIPANTS: TEMPO-1 was a phase 3, double-blind, placebo-controlled randomized clinical trial conducted at 102 sites across 12 countries between December 2019 and June 2024. Adults with early PD (<3 years' disease duration) who were treatment naive or had less than 3 months of prior dopaminergic treatment were eligible for enrollment. Data analysis was completed from July 2024 to May 2025. INTERVENTION: Participants were randomized 1:1:1 to receive 1 of 2 fixed doses of tavapadon (5 or 15 mg once daily) or placebo for 27 weeks, followed by a 4-week safety follow-up period. MAIN OUTCOMES AND MEASURES: The primary end point was least-squares mean (LSM) change from baseline to week 26 in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) parts II and III combined score. Key secondary end points were LSM change from baseline to week 26 in MDS-UPDRS part II scores and the proportion of participants with a score of "much improved" or "very much improved" on the Patient Global Impression of Change. RESULTS: Overall, 751 adults with early PD who were treatment naive or had less than 3 months of prior dopaminergic treatment were screened, and 529 participants were enrolled (187 female participants [35.3%]; mean [SD] age, 63.7 [9.6] years; mean [SD] disease duration, 0.7 [0.8] years) and randomized to receive tavapadon, 5 mg (n = 177), tavapadon, 15 mg (n = 177), or placebo (n = 175). The change from baseline to week 26 in the MDS-UPDRS parts II and III combined score was significantly improved in participants treated with both the 5-mg dose of tavapadon (9.7-point decrease vs 1.8-point increase with placebo; treatment difference, -11.5 points; 95% CI, -13.8 to -9.2; P < .001; d = 1.14) and 15-mg dose of tavapadon (10.2-point decrease vs 1.8-point increase with placebo; treatment difference, -12.1 points; 95% CI, -14.4 to -9.8; P < .001; d = 1.20). Tavapadon had a favorable safety profile; most AEs were nonserious and mild to moderate in severity. Common AEs with tavapadon were nausea (90 of 354 with tavapadon [25.4%]), headache (59 of 354 [16.7%]), and dizziness (45 of 354 [12.7%]). CONCLUSIONS AND RELEVANCE: In the TEMPO-1 randomized clinical trial, tavapadon improved motor function in participants with early PD and was well tolerated with a favorable safety profile. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04201093.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Flowchart of Participant Disposition a Received ≥1 dose of placebo or tavapadon as randomized (safety analysis set). b Efficacy assessed in modified intent-to-treat (mITT) population, which included all randomized participants who received ≥1 dose of the study drug and had both a baseline and ≥1 postbaseline Movement Disorder Society–Unified Parkinson’s Disease Rating Scale assessment.
非 KM Figure
Figure 2.Line Graphs Depicting Least-Squares Mean (LSM) Change From Baseline in Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Scores (A) and Part II Scores (B) a Nominal P < .001. b Nominal P < .01. c Modified intent-to-treat population (all randomized participants who received ≥1 dose of the study drug and had both a baseline and ≥1 postbaseline MDS-UPDRS assessment).
非 KM Figure